New Drug Cuts Kids' Seizures 80% in UK Trial

Children with a rare, treatment-resistant form of epilepsy saw their seizures drop by 80% after taking a new drug in a clinical trial at Great Ormond Street Hospital in London.

The trial tested Zorevunersen on 81 children ages 2 to 18 who have Dravet syndrome, a genetic condition that affects about 3,000 children in England. These kids suffered up to 18 seizures every month before treatment.

After just one dose, monthly seizures dropped by half. After three doses, that reduction jumped to 80%. All 81 patients tolerated the medication well, with no serious side effects reported.

The results go beyond just fewer seizures. Children in the trial showed real improvements in motor skills and communication. Their ability to cope with daily life got better too.

Professor Helen Cross, who led the trial at University College London, regularly treats children who need around-the-clock care because of their epilepsy. Many can't do anything independently, and they face a high risk of sudden death from seizures.

She believes Zorevunersen could help these children "lead much healthier and happier lives." A phase 3 trial is now being organized to study the drug's effects over a longer period.

The Ripple Effect

This success matters beyond Dravet syndrome alone. Scientists not involved in the research say it proves that pharmaceutical treatments can work for genetic epilepsies, a category that includes over 800 different conditions.

Dr. Alfredo Gonzalez-Sulser from the University of Edinburgh told reporters this breakthrough "sets a clear path" for developing treatments for other severe epilepsies. For hundreds of genetic epilepsy types that currently have no treatment options, this trial offers a roadmap.

The advancement could spark a wave of innovation, giving thousands of families worldwide hope for medications that might transform their children's lives.

Zorevunersen represents more than just one successful drug trial: it's proof that conditions once considered untreatable might have solutions waiting to be discovered.